By Colin Kellaher
Harmony Biosciences Holdings said the Food and Drug Administration has turned away its application seeking expanded approval of its Wakix narcolepsy drug for the treatment of excessive daytime sleepiness in adults with the chronic sleep disorder idiopathic hypersomnia.
Harmony on Wednesday said the FDA issued a "refusal-to-file" letter, which indicates that an application is incomplete and won't be reviewed.
Harmony last year filed for the expanded approval of pitolisant, as Wakix is known generically, despite the drug missing its primary endpoint in a Phase 3 study in patients with idiopathic hypersomnia.
The Plymouth Meeting, Pa., company termed the FDA's refusal to file a short-term setback and said its long-term strategy for pitolisant in idiopathic hypersomnia is on track with its focus on a higher-dose formulation of the drug.
Harmony said it expects to launch a Phase 3 registrational study of pitolisant HD in the fourth quarter, with a target of FDA approval in idiopathic hypersomnia in 2028.
The company noted that the setback doesn't change its 2025 revenue guidance of $820 million to $860 million.
Harmony shares were recently down 8.1% to $35.93 in early trading Wednesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 19, 2025 09:55 ET (14:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。